LNC Therapeutics, a French company specializing in the research and development of gut microbiota directed drugs for the treatment of obesity and associated cardiometabolic diseases, raised €6.5 million ($7.7 million) in Series C funding.
In the same category
LNC Therapeutics selected by BNP Paribas for its innovative approach to beat obesity
Nov 12, 2019more +
Avec plus de 140 millions d’euros levés, les startups ne ratent pas leur rentrée
Sep 6, 2019more +
LNC Therapeutics raises €6.2 million for the clinical development of new generation gut microbiome...
Sep 5, 2019more +